Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Drugs For Benign Prostatic hypertrophy Market In 2029?
The market for benign prostatic hypertrophy drugs has seen substantial growth in the past few years. Its growth is set to continue, going from a market value of $4.28 billion in 2024, to around $4.58 billion in 2025, at a compound annual growth rate (CAGR) of 6.8%. The factors contributing to this growth in the historical period include an aging population, enhanced awareness, progress in drug treatment therapies, and accessibility to healthcare.
What Growth Rate Is Forecasted for the Drugs For Benign Prostatic hypertrophy Market by 2029?
Expectations are high for significant expansion in the benign prostatic hypertrophy drugs market in the coming years. Analysts predict it will rise to a value of $5.58 billion by 2029, reflecting a compound annual growth rate (CAGR) of 5.1%. Factors contributing to growth during the forecast period involve rising markets, breakthroughs in drug development, growing awareness and education, and regulatory certifications. The period is also expected to see trends like minimally invasive procedures, customized medical treatments, combination therapies, patient-focused care, use of telemedicine and digital healthcare, as well as research and development.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2594&type=smp
Which Key Companies Are Shaping the Future of the Drugs For Benign Prostatic hypertrophy Market?
Major companies operating in the drugs for benign prostatic hypertrophy market include Allergan Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Sanofi S.A., Nymox Pharmaceutical Corporation, Æterna Zentaris Inc., Pfizer Inc., IntelGenx Technologies Corp., Ipsen S.A., Novartis International AG, Antibe Therapeutics Inc., Bausch Health Companies Inc., Bayer AG, Quest PharmaTech Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Impax Laboratories Inc., GemVax & KAEL Inc., Merck & Co. Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Allium Medical Solutions Ltd., Asahi Kasei Corporation, Asclepion Laser Technologies GmbH, Boston Scientific Corporation, Biolitec AG, Coloplast A/S, Eli Lilly and Company, Endo International plc, IPG Photonics Corporation, KARL STORZ SE & Co. KG, LISA Laser Products AG, Medifocus Inc., Olympus Corporation, Pharex Health Corporation, PNN Medical A/S, Quanta S.p.A.
Which Factors Are Driving Demand in the Drugs For Benign Prostatic hypertrophy Industry?
The accelerated growth of the global Benign Prostatic Hypertrophy drug market is attributed to an increasing male geriatric population as Benign Prostatic Hypertrophy is a typical condition found in men over 50 years of age. For example, as reported by the World Health Organization, a specialized health agency from the US, in October 2022, by the year 2030, 1 in every 6 individuals around the globe will be 60 years or above, and the number of elderly people is predicted to hit 2.1 billion by 2050. The National Institute of Health (NIH) further adds that Benign Prostatic Hyperplasia affects approximately 50% of men aged between 51 and 60 years, and as many as 90% of men who are more than 80 years old.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=2594&type=smp
How Is the Drugs For Benign Prostatic hypertrophy Market Segmented by Several Divisions?
The drugs for benign prostatic hypertrophy market covered in this report is segmented –
1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users
Subsegments:
1) By Alpha Blocker: Tamsulosin, Alfuzosin, Doxazosin, Terazosin, Silodosin
2) By 5-alpha Reductase Inhibitor: Finasteride, Dutasteride
3) By Phosphodiesterase-5 Inhibitor: Tadalafil, Sildenafil
4) By Other Types: Anticholinergics, Herbal Supplements (Saw Palmetto), Combination Therapy Drugs (Alpha Blocker + 5-alpha Reductase Inhibitor)
What are the Emerging Market Trends Driving the Growth of the Drugs For Benign Prostatic hypertrophy Industry?
Prominent businesses involved in the benign prostatic hypertrophy drug market are concentrating their efforts on creating innovative treatments such as Polish medicines. These drugs help diagnose, treat, prevent or alleviate the symptoms of diseases and conditions and are regulated for safety, efficacy, and quality by health bodies. A notable example comes from Adamed Sp. z o.o, a pharmaceutical company based out of Poland, who introduced a combination drug, namely solifenacin succinate + tamsulosin hydrochloride in June 2023. These medications work jointly within a fixed-dose treatment to effectively deal with lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH). The mixture of both drugs enhances the therapeutic impact by decreasing bladder contractions through solifenacin while promoting urination with tamsulosin. This leads to improved patient results as opposed to utilizing tamsulosin alone.
Access The Full Report Here:
Which Regions Are Driving Growth in the Drugs For Benign Prostatic hypertrophy Market?
North America was the largest region in the drugs for benign prostatic hypertrophy market in 2023. Middle East is expected to be the fastest-growing region in the drugs for benign prostatic hypertrophy market. The regions covered in the drugs for benign prostatic hypertrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2594
This Report Delivers Insight On:
1. How big is the drugs for benign prostatic hypertrophy market, and how is it changing globally?
2. Who are the major companies in the drugs for benign prostatic hypertrophy market, and how are they performing?
3. What are the key opportunities and risks in the drugs for benign prostatic hypertrophy market right now?
4. Which products or customer segments are growing the most in the drugs for benign prostatic hypertrophy market?
5. What factors are helping or slowing down the growth of the drugs for benign prostatic hypertrophy market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model